Literature DB >> 17549396

Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review).

Lin Ye1, Howard G Kynaston, Wen G Jiang.   

Abstract

Prostate cancer is the most common cancer in men in Western countries, with a high incidence of bone metastasis. The bony metastasis is incurable and contributes significantly to disease-specific morbidity and mortality. The molecular and cellular mechanisms leading to the development of bone metastasis in prostate cancer remain unclear, but are currently under intensive investigation. In this review, we summarized the current understanding of bone metastasis in prostate cancer. The rapid progress in the genetic predisposition that makes prostate cancer cells more prone to spread to bone, bone-derived factors which are involved in the development of bone metastasis at the level of the local microenvironment, the interactions between metastatic prostate cancer cells and bone marrow endothelial cells, osteoblasts, and osteoclasts, are discussed in this article.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549396

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  24 in total

Review 1.  Recent advances in bone-targeted therapies of metastatic prostate cancer.

Authors:  Xiyun Deng; Guangchun He; Junwen Liu; Feijun Luo; Xiaoning Peng; Shigang Tang; Zhiyong Gao; Qinlu Lin; Jill M Keller; Tao Yang; Evan T Keller
Journal:  Cancer Treat Rev       Date:  2014-04-16       Impact factor: 12.111

2.  Role of hepcidin and iron metabolism in the onset of prostate cancer.

Authors:  Bin Zhao; Ruiqian Li; Gang Cheng; Zhiyao Li; Zhiping Zhang; Jun Li; Guoying Zhang; Chengwei Bi; Chen Hu; Libo Yang; Yonghong Lei; Qilin Wang
Journal:  Oncol Lett       Date:  2018-04-20       Impact factor: 2.967

3.  Decreased expression of ferroportin in prostate cancer.

Authors:  Dong Xue; Cui-Xing Zhou; Yun-Bo Shi; Hao Lu; Xiao-Zhou He
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

4.  Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line.

Authors:  Sweta Mishra; Yuping Tang; Long Wang; Linda deGraffenried; I-Tien Yeh; Sherry Werner; Dean Troyer; John A Copland; Lu-Zhe Sun
Journal:  Prostate       Date:  2011-02-14       Impact factor: 4.104

Review 5.  Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.

Authors:  Shawn Spencer; Bernard L Marini; William D Figg
Journal:  Anticancer Res       Date:  2012-07       Impact factor: 2.480

Review 6.  Where Hematopoietic Stem Cells Live: The Bone Marrow Niche.

Authors:  Krzysztof Szade; Gunsagar S Gulati; Charles K F Chan; Kevin S Kao; Masanori Miyanishi; Kristopher D Marjon; Rahul Sinha; Benson M George; James Y Chen; Irving L Weissman
Journal:  Antioxid Redox Signal       Date:  2018-01-09       Impact factor: 8.401

7.  Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis.

Authors:  Diptiman Chanda; Tatyana Isayeva; Sanjay Kumar; Jonathan A Hensel; Anandi Sawant; Girish Ramaswamy; Gene P Siegal; Matthew S Beatty; Selvarangan Ponnazhagan
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

Review 8.  Bone metastasis: pathogenesis and therapeutic implications.

Authors:  Philippe Clezardin; Anna Teti
Journal:  Clin Exp Metastasis       Date:  2007-11-16       Impact factor: 5.150

9.  Curcumin blocks CCL2-induced adhesion, motility and invasion, in part, through down-regulation of CCL2 expression and proteolytic activity.

Authors:  Jeffery G Herman; Henry L Stadelman; Charles E Roselli
Journal:  Int J Oncol       Date:  2009-05       Impact factor: 5.650

10.  Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT.

Authors:  Xinsheng Peng; Wei Guo; Tiejian Liu; Xi Wang; Xiang'an Tu; Dafu Xiong; Song Chen; Yingrong Lai; Hong Du; Guangfu Chen; Guanglin Liu; Yubo Tang; Shuai Huang; Xuenong Zou
Journal:  PLoS One       Date:  2011-05-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.